# EDGAR Filing Document

**Accession Number:** 0001711933
**File Stem:** 0001104659-23-003149
**Filing Date:** 2023-1
**Character Count:** 9391
**Document Hash:** 790b99d0783b6bab5c304742b8fa3471
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-003149.hdr.sgml**: 20230112

**ACCESSION NUMBER**: 0001104659-23-003149

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 13

**CONFORMED PERIOD OF REPORT**: 20230108

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230112

**DATE AS OF CHANGE**: 20230111

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Akoya Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001711933
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY ANALYTICAL INSTRUMENTS [3826]
- **IRS NUMBER:** 475586242
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40344
- **FILM NUMBER:** 23524553

**BUSINESS ADDRESS:**
- **STREET 1:** 100 CAMPUS DRIVE
- **STREET 2:** 6TH FLOOR
- **CITY:** MARLBOROUGH
- **STATE:** MA
- **ZIP:** 01762
- **BUSINESS PHONE:** 855.896.8401

**MAIL ADDRESS:**
- **STREET 1:** 100 CAMPUS DRIVE
- **STREET 2:** 6TH FLOOR
- **CITY:** MARLBOROUGH
- **STATE:** MA
- **ZIP:** 01762

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d)** 

**OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): January 8, 2023

**Akoya Biosciences, Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-40344** | **47-5586242** |
| (State or other jurisdiction <br> of incorporation) | (Commission <br> File Number) | (IRS Employer <br> Identification No.) |

---

---

| | |
|:---|:---|
| **100 Campus Drive, 6th Floor**<br> **Marlborough, MA**<br> (Address of principal executive offices) | **01752**<br> (Zip Code) |

---

**(855) 896-8401**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol | Name of each exchange on which registered |
| **Common stock, par value $0.00001 per share** | **AKYA** | **The Nasdaq Stock Market LLC** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ⌧

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

---

| | |
|:---|:---|
| **Item 2.02** | **Results of Operations and Financial Condition.** |

---

On January 8, 2023, Akoya Biosciences, Inc. (the "***Company***") issued a press release announcing its preliminary unaudited financial results for the three months and full-year ended December 31, 2022. A copy of this release is furnished as Exhibit 99.1 hereto.

*The information under Item 2.02 of this Current Report on Form 8-K, including the press release furnished as Exhibit 99.1, is being furnished, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any of the Company's filings, whether made before or after the date hereof, regardless of any general incorporation language in any such filing*.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description of Exhibits** |
| [99.1](tm233229d1_ex99-1.htm) | [Press Release, dated January 8, 2023](tm233229d1_ex99-1.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: January 12, 2023 | **Akoya Biosciences, Inc.** | **Akoya Biosciences, Inc.** |
|  | By: | */s/ Brian McKelligon*  |
|  |  | Brian McKelligon |
|  |  | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**Akoya Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2022**

MARLBOROUGH, Mass. — January 8, 2023 — Akoya Biosciences, Inc. (Nasdaq: AKYA) ("Akoya"), The Spatial Biology Company®, today announced preliminary unaudited revenue for the fourth quarter and full year ended December 31, 2022.

Akoya reported the following preliminary financial results for the fourth quarter and full year 2022, which remain subject to quarter end closing adjustments:

&nbsp;&nbsp;&nbsp;&nbsp;· Revenue for the fourth quarter of 2022 is expected to be between $20.7 million and $21.2 million, as compared to $16.2 million for
the corresponding quarter of last year

&nbsp;&nbsp;&nbsp;&nbsp;· For the fiscal year of 2022, revenue is expected to be between $74.3 million and $74.8 million, as compared to $54.9 million for fiscal
year 2021

"The fourth quarter of 2022 was another record quarter for Akoya, demonstrating our continued business momentum and commercial execution," said Brian McKelligon, Chief Executive Officer. "In 2022, we delivered strong financial performance and saw growing adoption of our spatial biology platforms across the discovery, translational, and clinical markets."

A link to a webcast replay of Akoya's 2<sup>nd</sup> annual Spatial Day, which took place virtually on December 15, 2022, can be found below:

<u>Akoya Biosciences Spatial Day 2022 \| Akoya</u>

The financial results in this press release reflect expectations based on currently available information. The company has yet to complete its quarter end closing and actual results are therefore subject to change.

**Use of forward-looking statements**

This press release contains forward-looking statements that are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our fourth quarter 2022 revenue outlook.

In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under the captions "Risk Factors," and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

**About Akoya Biosciences**

As The Spatial Biology Company®, Akoya Biosciences' mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels and PhenoCycler®, PhenoImager® Fusion and PhenoImager HT Instruments. To learn more about Akoya, visit <u>www.akoyabio.com</u>.

**Investor Contact:**

Priyam Shah<br> Sr. Director, Investor Relations<br> Akoya Biosciences, Inc.<br> <u>investors@akoyabio.com</u>

**Media Contact:**

Christine Quern<br> (617) 650-8497<br> <u>media@akoyabio.com</u>